Fda approves abbott's new spinal cord stimulation device; provides tailored relief to multiple pain areas and adds more treatment options for evolving pain conditions

Abbott's new proclaim™ plus spinal cord stimulation (scs) system offers the next generation of stimulation therapy, giving physicians the ability to treat multi-site and evolving pain the system builds on the company's proprietary therapy, burstdr™ stimulation, that works by mimicking natural patterns found in the brain1 to deliver superior pain relief2,3 and is preferred to traditional "tingling" tonic stimulation by 87% of patients4 the proclaim plus scs system can be used in conjunction with abbott's neurosphere™ virtual clinic, which allows people to connect with their doctor and receive remote programming adjustments from the comfort of their home* abbott park, ill., aug. 23, 2022 /prnewswire/ -- abbott (nyse: abt) today announced that the u.s. food and drug administration (fda) has approved its new proclaim™ plus spinal cord stimulation (scs) system featuring flexburst360™ therapy.
ABT Ratings Summary
ABT Quant Ranking